



**The CytoTools AG announces change in management board and a strategy alteration of the operational companies.**

- The CytoTools AG announces that Dr. med. Wilfried Hauke is leaving the board for personal reasons
- Dr. Wilfried Hauke planned and initiated the development strategy for the upcoming clinical trials and the certification of the medical product
- The future strategy envisages markedly strengthening the management of the holdings DermaTools Biotech GmbH and CytoPharma GmbH

Darmstadt, 31<sup>st</sup> May 2017 – The CytoTools AG, a technology holding company with participations in the pharmaceutical and medical products fields, announces a change in the management board: Dr. Wilfried Hauke is leaving the board for personal reasons. He has completed the complete clinical development strategy as well as the strategy for medical product certification and, in future, will be available to the CytoTools AG as a consultant. The CytoTools AG thanks Dr. Hauke for the formulation of the new development strategy.

Concomitant with the change in strategy, new experienced managers will be appointed for the fields medicine, clinical development and registration. They will come from the internationally operating pharmaceutical and medical products industry and will be appointed CEOs of the subsidiary companies. Suitable candidates are available and they will be presented shortly. In this way, the prerequisites are to be created so that the coming tasks can now be dealt with quickly and effectively. The development of a medical product has already begun and, already in the current year, the clinical development of the wound healing active substance DermaPro<sup>®</sup> is to be continued after successful financing.

The upcoming appointment of the new CEO of DermaTools Biotech GmbH will create and concentrate operative competence directly in the DermaTools company itself. This should achieve the important goal of commencing the repeat of the clinical phase DermaPro<sup>®</sup> in this year and bringing the trials to a successful conclusion within the planned time frame.

The CytoTools CEO, Dr. Mark-Andre Freyberg summarized: „Thanks to the planning which has been completed by Dr. Hauke, the CytoTools AG now has a clear strategy for the realisation of its “Derma-Pipeline”.

The change in strategy towards a strengthening of the management level of DermaTools will mean we can reach our goals faster and more effectively. With the medical product development which has now commenced, we will soon contact possible partners and thus be able to place an interesting product on the market.“

*This press release contains specific future oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future-oriented statements made. CytoTools is not obligated to update these future-oriented statements.*

CytoTools AG, previously CytoTools GmbH, is a technology holding and participating company which holds shares in its subsidiary companies with product developments in the pharmaceutical and medical products fields: about ca. 57 % of the DermaTools Biotech GmbH (therapy field dermatology, urology) and 42 % of the CytoPharma GmbH (therapy field cardiovascular disease, cancer). The complete know-how is protected by corresponding basic patents which are maintained worldwide and which are transferred to the subsidiary companies in the form of worldwide exclusive licenses

**Contact:**

CytoTools AG

Dr. Mark-André Freyberg

Klappacher Str. 126

D-64285 Darmstadt

Tel.: +49-6151-95158-12

Fax: +49-6151-95158-13

E-Mail: [freyberg@cytotools.de](mailto:freyberg@cytotools.de)